Over 247 million women worldwide use hormonal contraception – the majority with combined oral contraceptives (COCs). This prevalence is accompanied by an ongoing medical responsibility: venous thromboembolism, ischemic strokes and myocardial infarctions are rare but potentially life-threatening side effects that must be assessed according to the preparation, route of administration and individual risk profile. A groundbreaking cohort study from Denmark [1], which analyzed data from over two million women over 22 years, provides granular risk data for modern forms of contraception for the first time. At the same time, new substances – estetrol (E4), nomegestrol acetate (NOMAC) and the drospirenone-only pill – are expanding the therapeutic spectrum.
Jetzt beitreten
